ABUS icon

Arbutus Biopharma

111 hedge funds and large institutions have $152M invested in Arbutus Biopharma in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 30 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

more call options, than puts

Call options by funds: $ | Put options by funds: $

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more ownership

Funds ownership:

more funds holding in top 10

Funds holding in top 10:

9% less funds holding

Funds holding: 122111 (-11)

19% less capital invested

Capital invested by funds: $189M → $152M (-$36.9M)

45% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 22

Holders
111
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$2.34M
Puts
$1.13M
Net Calls
Net Calls Change

Top Sellers

1 -$1.84M
2 -$1.51M
3 -$848K
4
Two Sigma Investments
Two Sigma Investments
New York
-$709K
5
JPMorgan Chase & Co
JPMorgan Chase & Co
New York
-$435K
Name Holding Trade Value Shares
Change
Change in
Stake
1
$22.9M
2
$19M
3
$18.6M
4
$13.4M
5
$11.7M
6
$7.81M
7
$6.55M
8
$5.98M
9
$5.68M
10
$5.28M
11
$5.08M
12
$3.92M
13
$3.14M
14
$3.09M
15
$2.4M
16
$1.88M
17
$1.13M
18
$1.07M
19
$1.04M
20
$904K
21
$773K
22
$755K
23
$739K
24
$716K
25
$676K